Form 4: Stoke Therapeutics Director Sells Shares for Tax

Stoke Therapeutics Director Edward M. Kaye, MD, sold 12,126 shares of common stock to cover tax withholding liabilities related to restricted stock unit vesting.

Summary

• Edward M. Kaye, MD, a Director of Stoke Therapeutics, Inc. (STOK), sold 12,126 shares of common stock.
• The sale occurred on August 18, 2025, at a weighted average price of $18.238 per share.
• The shares were sold in multiple transactions ranging from $18.00 to $18.50 per share.
• This transaction was an issuer-mandated sale to satisfy tax withholding liabilities associated with the vesting and settlement of restricted stock units.
• Following this transaction, Edward M. Kaye, MD, beneficially owns 153,470 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, issuer-mandated sale to cover tax liabilities from equity vesting, which is a neutral event and does not reflect a discretionary decision by the director regarding the company's prospects.

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine, non-discretionary sale for tax purposes, not indicative of a change in confidence by the director.

Key Dates

Recommendation

The transaction is a routine, issuer-mandated sale by a director to cover tax obligations arising from restricted stock unit vesting. It does not signal a change in the director's confidence in the company's future prospects or represent a discretionary sale. Therefore, it provides no new information to warrant a change in investment recommendation based solely on this filing.

Keywords

Stoke Therapeutics, STOK, Edward M. Kaye, Director, Stock Sale, Form 4, Insider Trading, Restricted Stock Units, Tax Withholding